Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the company's pricing practices for its product Eylea during the class period from November 2, 2023, to October 30, 2024 [1]. Summary by Sections Allegations - The complaint alleges that Regeneron made materially false and misleading statements by failing to disclose payments made to distributors to subsidize credit card fees for Eylea customers [1] - These undisclosed payments led to a price concession that lowered Eylea's selling price, providing a competitive advantage in a sensitive pricing environment for retina practices [1] - As a result, Regeneron allegedly overstated Eylea sales and misrepresented its business operations and prospects, violating the False Claims Act by not reporting these payments as price concessions [1] Class Action Details - Shareholders who purchased shares of REGN during the specified class period are encouraged to register for the class action, with a deadline set for March 10, 2025 [2] - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, and there is no cost or obligation to participate [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - Regeneron Pharmaceuticals has faced challenges in the past year, particularly with its Eylea product, leading to a 30% decline in stock price, but there are strong reasons to consider it a long-term investment opportunity [1] Group 1: Eylea's Performance - Eylea, a treatment for wet age-related macular degeneration, has seen slowed sales growth due to increased competition, including a biosimilar from Amgen, resulting in only a 2% year-over-year sales increase to $1.5 billion in the fourth quarter [2][3] - The decline in Eylea's performance has raised concerns among investors, but the overall revenue for Regeneron grew by 10% year over year to $3.8 billion, largely driven by Dupixent [3] Group 2: Dupixent's Growth - Dupixent, co-marketed with Sanofi, experienced a 15% year-over-year sales increase to $3.7 billion, making it one of the top-selling drugs globally [4] - Regeneron and Sanofi are pursuing label expansions for Dupixent, including a new indication for treating bullous pemphigoid, which could further boost sales [5] Group 3: Innovative Pipeline - Regeneron is developing a promising gene therapy for congenital deafness, showing positive results in early-stage trials, with 10 out of 11 patients experiencing improved hearing [6][7] - The ongoing development of innovative treatments positions Regeneron well for future growth beyond Eylea and Dupixent [8] Group 4: Capital Return to Shareholders - Regeneron has announced a quarterly dividend of $0.88 and is actively engaging in a stock buyback program, indicating a commitment to returning capital to shareholders [9] - The company's strong operational performance supports the sustainability of its dividend program [9] Group 5: Overall Investment Appeal - Regeneron's ability to innovate, robust operational performance, and prudent capital allocation make it an attractive investment option despite recent stock price declines [10]

Core Insights - Dupixent (dupilumab) shows significant efficacy in achieving sustained disease remission in adults with moderate-to-severe bullous pemphigoid (BP), with five times more patients achieving remission compared to placebo at 36 weeks [1][5] - The drug also significantly reduces disease severity and itch, as well as the use of oral corticosteroids and rescue medications compared to placebo [1][5] - Regulatory submissions for Dupixent to treat BP are currently under review in the U.S. and the European Union, with a decision from the FDA expected by June 20, 2025 [3][5] Group 1: Clinical Trial Results - The ADEPT Phase 2/3 trial enrolled 106 adults with moderate-to-severe BP, demonstrating that 20% of Dupixent-treated patients achieved sustained disease remission compared to 4% in the placebo group (p=0.0114) [2][5] - Additionally, 40% of Dupixent patients achieved a ≥90% reduction in disease severity compared to 10% in the placebo group (p=0.0003) [5] - The average cumulative oral corticosteroid exposure was reduced by 1678 mg (p=0.0220), and there was a 54% lower risk of rescue medication use (p=0.0016) in the Dupixent group [5] Group 2: Safety Profile - Adverse events (AEs) were reported at a rate of 96% for both Dupixent and placebo groups, with specific AEs more common in the Dupixent group including peripheral edema (n=8 vs. n=5) and arthralgia (n=5 vs. n=3) [3] - No AEs led to death in the Dupixent group, while two AEs led to death in the placebo group [3] Group 3: Regulatory and Market Context - Dupixent has received Orphan Drug Designation from the FDA for BP, which is applicable to treatments for rare diseases affecting fewer than 200,000 people in the U.S. [3] - The drug has been approved in over 60 countries for various indications, with more than 1,000,000 patients currently treated globally [10]

SAN FRANCISCO, March 06, 2025 (GLOBE NEWSWIRE) -- Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024.   Hagens Berman urges investors who purchased Regeneron shares and suffered s ...

It has been about a month since the last earnings report for Regeneron (REGN) . Shares have lost about 4.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Regeneron due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Regeneron Beats on Q4 Earnings, Initiates Quarterl ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=134032&from=4 CLAS ...

Core Insights - The report titled "Inclusion Body Myositis - Pipeline Insight, 2025" provides a comprehensive overview of the current pipeline for Inclusion Body Myositis (IBM), highlighting the efforts of over 2 companies and the development of more than 3 pipeline drugs projected until 2025 [2][4]. Group 1: Understanding Inclusion Body Myositis - Inclusion Body Myositis is a progressive muscle disorder primarily affecting adults over 50, with an estimated patient population exceeding 50,000 in the U.S. and Europe [3]. - The report addresses both symptomatic and pathophysiological aspects of IBM, along with insights into diagnostic methodologies and current treatment paradigms [3]. Group 2: Current Treatment Landscape - There are currently no approved therapeutic options specifically for IBM, and existing treatments like immunosuppressants and corticosteroids have shown limited efficacy [4]. - The report discusses various strategies under investigation to meet the unmet medical needs in this therapeutic area [4]. Group 3: Advancements in the Therapeutic Pipeline - The report highlights emerging drugs in the IBM pipeline, including ABC008 by Abcuro, Inc., which is an anti-KLRG1 antibody currently in Phase II/III trials targeting cytotoxic T cells involved in IBM [5]. Group 4: Strategic Developments and Future Outlook - The report details pipeline development activities such as collaborations, acquisitions, mergers, and licensing that are shaping the future of IBM treatments [6]. - These strategic developments may provide new pathways for improving care and management for individuals affected by IBM [6].

PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of purchasers of Regeneron securities between November 2, 2023 through October 30, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired REGENERON securities during the Class Period may, no later than MARCH 10, 2025, seek to be appointed as a ...

Group 1 - Regeneron Pharmaceuticals participated in the TD Cowen 45th Annual Health Care Conference, highlighting its ongoing engagement with investors and analysts [1] - Marion McCourt, Chief Commercial Officer, and Ryan Crowe, Senior Vice President of Investor Relations, represented the company during the conference [1] - The conference included a forward-looking statement disclaimer, indicating that remarks may involve risks and uncertainties that could affect actual results [3] Group 2 - The discussion began with a focus on the EYLEA franchise, with inquiries about its latest developments and key catalysts for growth in 2025 [4]

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/regeneron-ph ...